JP2005534660A5 - - Google Patents

Download PDF

Info

Publication number
JP2005534660A5
JP2005534660A5 JP2004511274A JP2004511274A JP2005534660A5 JP 2005534660 A5 JP2005534660 A5 JP 2005534660A5 JP 2004511274 A JP2004511274 A JP 2004511274A JP 2004511274 A JP2004511274 A JP 2004511274A JP 2005534660 A5 JP2005534660 A5 JP 2005534660A5
Authority
JP
Japan
Prior art keywords
formula
substituted
groups
conha
cooa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004511274A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005534660A (ja
JP4511925B2 (ja
Filing date
Publication date
Priority claimed from DE10224888A external-priority patent/DE10224888A1/de
Application filed filed Critical
Publication of JP2005534660A publication Critical patent/JP2005534660A/ja
Publication of JP2005534660A5 publication Critical patent/JP2005534660A5/ja
Application granted granted Critical
Publication of JP4511925B2 publication Critical patent/JP4511925B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004511274A 2002-06-05 2003-05-12 ピリダジン誘導体 Expired - Fee Related JP4511925B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10224888A DE10224888A1 (de) 2002-06-05 2002-06-05 Pyridazinderivate
PCT/EP2003/004930 WO2003104204A1 (de) 2002-06-05 2003-05-12 Pyridazinderivate

Publications (3)

Publication Number Publication Date
JP2005534660A JP2005534660A (ja) 2005-11-17
JP2005534660A5 true JP2005534660A5 (enExample) 2006-06-29
JP4511925B2 JP4511925B2 (ja) 2010-07-28

Family

ID=29594275

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004511274A Expired - Fee Related JP4511925B2 (ja) 2002-06-05 2003-05-12 ピリダジン誘導体

Country Status (17)

Country Link
US (2) US7129241B2 (enExample)
EP (1) EP1509506B1 (enExample)
JP (1) JP4511925B2 (enExample)
KR (1) KR20050009735A (enExample)
CN (1) CN1659147A (enExample)
AR (1) AR040141A1 (enExample)
AT (1) ATE438628T1 (enExample)
AU (1) AU2003227746B2 (enExample)
BR (1) BR0311343A (enExample)
CA (1) CA2488372C (enExample)
DE (2) DE10224888A1 (enExample)
ES (1) ES2329670T3 (enExample)
MX (1) MXPA04012009A (enExample)
PL (1) PL371918A1 (enExample)
RU (1) RU2004139032A (enExample)
WO (1) WO2003104204A1 (enExample)
ZA (1) ZA200500071B (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
MX2007012794A (es) 2005-04-13 2008-02-22 Astion Pharma As Composiciones para el tratamiento de trastornos del tejido conectivo de la piel.
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MY144906A (en) 2005-10-21 2011-11-30 Novartis Ag Human antibodies against il13 and therapeutic uses
GB2431927B (en) * 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AR060607A1 (es) 2006-04-21 2008-07-02 Novartis Ag Derivados de purina,composiciones farmaceuticas que los contienen, metodo de preparacion y usos en enfermedades obstructivas o inflamatorias de las vias respiratorias.
WO2007140189A2 (en) * 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
BRPI0717564A2 (pt) 2006-09-29 2013-10-22 Novartis Ag Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
US20080176901A1 (en) 2007-01-10 2008-07-24 Irm Llc Compounds and compositions as channel activating protease inhibitors
AU2008248598B2 (en) 2007-05-07 2011-11-17 Novartis Ag Organic compounds
ES2654395T3 (es) 2007-12-10 2018-02-13 Novartis Ag Análogos de amilorida espirocíclicos como bloqueantes de ENaC
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
WO2009092040A2 (en) * 2008-01-17 2009-07-23 Gary Dean Bennett Topical pain formulation
EP2300010B1 (en) 2008-06-10 2015-03-04 Novartis AG Pyrazine derivatives as epithelial sodium channel blockers
CA2744898A1 (en) * 2008-12-23 2010-07-01 Amira Pharmaceuticals, Inc. Topical formulations of flap inhibitors for administration to an eye
EP2381945A4 (en) * 2008-12-23 2012-06-13 Panmira Pharmaceuticals Llc TOPICAL FORMULAS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL DISEASES
DK2391366T3 (da) 2009-01-29 2013-01-07 Novartis Ag Substituerede benzimidazoler til behandling af astrocytomer
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
HRP20190016T1 (hr) 2009-08-17 2019-03-08 Intellikine, Llc Heterociklički spojevi i njihova upotreba
MX2012002179A (es) 2009-08-20 2012-03-16 Novartis Ag Compuestos heterociclicos de oxima.
EP2490689A4 (en) * 2009-10-19 2013-03-06 Panmira Pharmaceuticals Llc INJECTABLE FORMULATION FOR ADMINISTRATION IN OR NEAR RV
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
US20130324526A1 (en) 2011-02-10 2013-12-05 Novartis Ag [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
JP5959541B2 (ja) 2011-02-25 2016-08-02 ノバルティス アーゲー Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
WO2013038362A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
US9034879B2 (en) 2011-09-16 2015-05-19 Novartis Ag Heterocyclic compounds for the treatment of CF
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
WO2013149581A1 (en) 2012-04-03 2013-10-10 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
AU2013305759C1 (en) 2012-08-23 2018-01-18 Janssen Biopharma, Inc. Compounds for the treatment of paramoxyvirus viral infections
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2015162461A1 (en) 2014-04-24 2015-10-29 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
EA201692140A1 (ru) 2014-04-24 2017-04-28 Новартис Аг Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (pt) 2014-07-31 2017-11-21 Novartis Ag terapia de combinação
WO2016149126A1 (en) 2015-03-13 2016-09-22 The Board Of Trustees Of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
WO2018001948A1 (en) * 2016-06-29 2018-01-04 F. Hoffmann-La Roche Ag Pyridazinone-based broad spectrum anti-influenza inhibitors
JP2022537667A (ja) 2019-06-10 2022-08-29 ノバルティス アーゲー Ｃｆ、ｃｏｐｄ、及び気管支拡張症の治療のためのピリジン及びピラジン誘導体
EP4021572A1 (en) 2019-08-28 2022-07-06 Novartis AG Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
US11844792B2 (en) * 2020-07-10 2023-12-19 Sean Downing Treatment for severe acute respiratory illness associated with coronavirus
CN113143899A (zh) * 2021-05-13 2021-07-23 中国人民解放军陆军军医大学第二附属医院 辣椒素在制备治疗溃疡性结肠炎药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19632549A1 (de) 1996-08-13 1998-02-19 Merck Patent Gmbh Arylalkanoylpyridazine
DE19826841A1 (de) * 1998-06-16 1999-12-23 Merck Patent Gmbh Arylalkanoylpyridazine
DE19915364A1 (de) * 1999-04-06 2000-10-12 Merck Patent Gmbh Verwendung von Arylalkanoylpyridazinen
WO2001057025A1 (en) * 2000-01-31 2001-08-09 Pfizer Products Inc. Pyrimidine carboxamides useful as inhibitors of pde4 isozymes

Similar Documents

Publication Publication Date Title
JP2005534660A5 (enExample)
TW200635585A (en) Monocyclic substituted methanones
CA2407149A1 (en) Melanin-concentrating hormone antagonist
WO2010032147A3 (en) Hydroxamic acid derivatives useful as antibacterial agents
EA022459B1 (ru) Производные транилципромина в качестве ингибиторов гистон деметилаз lsd1 и/или lsd2
EA201490535A1 (ru) Пирролбензодиазепины
EA201591000A1 (ru) Пирролобензодиазепины
EP1679069A4 (en) NEW PIPERIDINE DERIVATIVE
EP1529047B8 (en) New purine derivatives
EA200500268A1 (ru) Производные диоксан-2-алкилкарбаматов, способ их получения и применение в терапии
EA200501477A1 (ru) Производные пиперидинил- и пиперазинилалкилкарбаматов, способы их получения и применение их в терапии
YU58701A (sh) Derivati tioamida
MY145298A (en) Chemical process
JP2009501198A5 (enExample)
EP1117297A4 (en) ECTEINASCIDIN-743 SYNTHETIC ANALOGS
JP2010529994A5 (enExample)
WO2008035381A3 (en) Process for the preparation of amine derivatives as calcimimetics
NZ605010A (en) Novel calcium salts of compound as anti-inflammatory, immunomodulatory and anti-proliferatory agents
SV2002000244A (es) Metodos y compuestos para inhibir mrp1 ref.x-13353
ATE404536T1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
BR0109048A (pt) Processo para a sìntese de citalopram
BRPI0409471B8 (pt) processo para preparação de 2-cianopirrolidinas n-substituídas
ATE409210T1 (de) Beschichtungsmittel
EP1500648A4 (en) NEW PIPERIDINE DERIVATIVES
GB0219052D0 (en) New puring derivatives